Chugai Pharmaceutical (TSE:4519) Stock Valuation After Recent Share Price Weakness

Chugai Pharmaceutical (TSE:4519) has drawn fresh attention after recent share price moves, with the stock down about 4.5% over the past month and roughly 20% over the past 3 months.

See our latest analysis for Chugai Pharmaceutical.

That recent 4.5% decline in the 1 month share price sits within a wider loss of about 20% over 3 months, even as the 1 year total shareholder return of 3.4% and 3 year total shareholder return of 87.7% point to a much stronger longer run outcome.

If this sort of volatility has you looking at other opportunities in healthcare and biotech, it could be worth scanning a wider set of healthcare AI stocks through the 7 healthcare AI stocks.

With Chugai’s share price sliding in recent months despite multi year total returns and analyst targets sitting above the current ¥7,450 level, the key question is whether the stock is undervalued today or whether the market is already pricing in future growth.

Most Popular Narrative: 25.3% Undervalued

At a last close of ¥7,450 against a widely followed fair value estimate of about ¥9,973, the current price sits well below that narrative view.

The company’s focus on biologics and personalized medicine, including advancements in mid-sized molecules (AUBE00) and a deep monoclonal antibody pipeline, is well aligned with increasing healthcare spending and the push for novel, high-value therapies, likely supporting future earnings expansion.

Read the complete narrative.

Want the full playbook behind that valuation gap? The narrative leans on higher revenue runways, richer margins, and a premium P/E multiple tied to those earnings.

Result: Fair Value of ¥9,973 (UNDERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, you also need to weigh risks such as heavy reliance on a few blockbuster drugs and potential pressure on margins from pricing changes and rising costs.

Find out about the key risks to this Chugai Pharmaceutical narrative.

Another View: Rich P/E Despite “Undervalued” Tag

That 25.3% discount to fair value sits awkwardly next to a P/E of about 27x, which is higher than both the peer average of 21.5x and the JP Pharmaceuticals industry average of 16.7x, even though the fair ratio for Chugai is estimated at 35.1x. Is this a bargain in progress or a premium that needs stronger proof?

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Sentiment looks mixed here, with solid long term returns set against richer multiples and real business risks. Consider acting quickly and stress test the story yourself by weighing the 4 key rewards and 1 important warning sign.

Looking for more investment ideas?

If Chugai does not fully fit your watchlist, broaden your search now and line up other candidates that match the type of opportunities you want to focus on.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com